电视辅助胸腔镜手术在晚期卵巢癌伴中大量胸腔积液初始治疗中的应用:纪念斯隆-凯特琳癌症中心Team Ovary研究
该研究评估电视辅助胸腔镜手术(VATS)在晚期卵巢癌伴中大量胸腔积液患者中界定胸腔内病变范围的作用。自2001年起,对疑似晚期卵巢癌伴中大量胸腔积液的患者行VATS;算法推荐胸腔内病变≤1cm行初始肿瘤细胞减灭术(PDS),>1cm行新辅助化疗(NACT)/间歇性肿瘤细胞减灭术(IDS)。共100例患者,中位总生存期44.5个月(95%CI:37.8-51.7)。PDS组生存期显著长于NACT/IDS组。
要点
- VATS可用于晚期卵巢癌伴中大量胸腔积液患者PDS与NACT/IDS的治疗决策。
- 胸腔内 macroscopic 病变≤1cm者推荐PDS,>1cm者推荐NACT/IDS。
- VATS下无macroscopic病变且行PDS者预后最佳,中位OS为87.8个月。
核心结论
- VATS有助于晚期卵巢癌伴中大量胸腔积液患者选择PDS还是NACT/IDS。
研究设计与样本
- 自2001年起,对疑似晚期卵巢癌伴中大量胸腔积液的患者行VATS评估胸腔内macroscopic病变。
- 算法推荐胸腔内病变≤1cm行PDS,>1cm行NACT/IDS。
- 中位年龄60岁,中位CA-125水平1158 U/mL,中位血清白蛋白3.8 g/dL。
主要发现
- 70例(70%)发现macroscopic胸膜病变。
- VATS后50例(50%)尝试行PDS(PDS组),50例(50%)接受NACT(NACT/IDS组),其中47例(94%)行IDS。
- 整个队列(n=100)中位总生存期(OS)为44.5个月(95%CI:37.8-51.7)。
- PDS组生存期显著长于NACT/IDS组:45.8个月(95%CI:40.5-87.8) vs 37.4个月(95%CI:33.3-45.2),p=0.016。
- 多变量分析中,macroscopic胸腔内病变(HR 2.18,95%CI:1.14-4.18;p=0.019)和年龄≥65岁(HR 1.98,95%CI:1.16-3.40;p=0.013)与死亡风险升高独立相关。
关键数值与推荐
- 算法推荐:胸腔内病变≤1cm行PDS,>1cm行NACT/IDS。
临床怎么用
- VATS可用于晚期卵巢癌伴中大量胸腔积液患者的治疗决策,以选择PDS或NACT/IDS。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We assessed the utility of video-assisted thoracic surgery (VATS) in defining extent of intrathoracic disease in advanced ovarian carcinoma with moderate-to-large pleural effusions. METHODS: Beginning in 2001, VATS was performed on all patients with suspected advanced ovarian carcinoma and moderate-to-large pleural effusions, evaluating for macroscopic intrathoracic disease. The algorithm recommended primary debulking surgery (PDS) for ≤1 cm, neoadjuvant chemotherapy (NACT)/interval debulking surgery (IDS) for >1 cm intrathoracic disease. We reviewed records of patients undergoing VATS from 10/01-01/19. Differences between treatment groups were tested using standard statistical techniques. RESULTS: One-hundred patients met eligibility criteria (median age, 60; median CA-125 level, 1158 U/mL; medium serum albumin, 3.8 g/dL). Macroscopic pleural disease was found in 70 (70%). After VATS, 50 (50%) underwent attempted PDS (PDS group), 50 (50%) received NACT (NACT/IDS group). Forty-seven (94%) underwent IDS. Median overall survival (OS) for the entire cohort (n = 100) was 44.5 months (95% CI: 37.8-51.7). The PDS group had significantly longer survival than the NACT/IDS group [45.8 (95% CI: 40.5-87.8) vs. 37.4 months (95% CI: 33.3-45.2); p = .016]. On multivariable analysis, macroscopic intrathoracic disease (HR 2.18, 95% CI: 1.14-4.18; p = .019) and age ≥ 65 (HR 1.98, 95% CI: 1.16-3.40; p = .013) were independently associated with elevated death risk. Patients with the best outcome had no macroscopic disease at VATS and underwent PDS (median OS, 87.8 months). CONCLUSIONS: VATS is useful in therapeutic decision-making for PDS vs. NACT/IDS in advanced ovarian cancer with moderate-to-large pleural effusions.
引用
- Boerner T, Filippova OT, Chi AJ, et al. Video-assisted thoracic surgery in the primary management of advanced ovarian carcinoma with moderate to large pleural effusions: A Memorial Sloan Kettering Cancer Center Team Ovary Study. Gynecol Oncol. 2020. PMID: 32792282. doi:10.1016/j.ygyno.2020.07.101
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。